Mark A. Reddish

3.0k citations

32 papers · 2.4k indexed · h-index 25

Impact in

Immunology top 2%
- Immunotherapy and Immune Responses
Infectious Diseases top 5%
- Antimicrobial Resistance in Staphylococcus

Papers in ⓘ

Molecular Biology 21
- Glycosylation and Glycoproteins Research 19
Radiology, Nuclear Medicine and Imaging 18
- Monoclonal and Polyclonal Antibodies Research 18

Co-authors: B. Michael Longenecker (22 shared papers)Grant D. MacLean (9 shared papers)R. Rao Koganty (12 shared papers)Mark J. Krantz (4 shared papers)Babita Agrawal (3 shared papers)James B. Dale (5 shared papers)Steven D. Stroop (3 shared papers)Alex Martin (1 shared paper)
Journals: Journal of Immunotherapy (4 papers)Cancer Immunology Immunotherapy (3 papers)International Journal of Cancer (3 papers)Infection and Immunity (2 papers)The Journal of Immunology (2 papers)
Partner nations: Canada United States India

In The Last Decade

Mark A. Reddish

32 papers receiving 2.3k citations

Peers

Countries citing papers authored by Mark A. Reddish

Since Specialization

Citations

This map shows the geographic impact of Mark A. Reddish's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Reddish with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Reddish more than expected).

Fields of papers citing papers by Mark A. Reddish

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Reddish. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Reddish. The network helps show where Mark A. Reddish may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark A. Reddish, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark A. Reddish Line = papers co-authored together Mark A. Reddish links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 Nature Medicine ·Babita Agrawal, Mark J. Krantz, Mark A. Reddish, B. Michael Longenecker	1998	252
2	Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers Clinical Infectious Diseases ·Shelly McNeil, Scott A. Halperin, Joanne M. Langley, B R Smith, Andrew E. Warren, Geoffrey P. Sharratt, Darlene Baxendale, Mark A. Reddish, Ming-Ye Hu, Steven D. Stroop, Joel Linden, Louis Fries, Peter Vink, James B. Dale	2005	232
3	Immunogenicity of a 26-Valent Group A Streptococcal Vaccine Infection and Immunity ·Mary C. Hu, Michael A. Walls, Steven D. Stroop, Mark A. Reddish, Bernard Beall, James B. Dale	2002	198
4	The Selectivity and Functional Connectivity of the Anterior Temporal Lobes Cerebral Cortex ·W. Kyle Simmons, Mark A. Reddish, Patrick S.F. Bellgowan, Alex Martin	2009	184
5	Antibodies Against Mucin-Associated Sialyl-Tn Epitopes Correlate with Survival of Metastatic Adenocarcinoma Patients Undergoing Active Specific Immunotherapy with Synthetic STn Vaccine Journal of Immunotherapy ·Grant D. MacLean, Mark A. Reddish, R. Rao Koganty, B. Michael Longenecker	1996	148
6	Enhancing the Effect of THERATOPE STn-KLH Cancer Vaccine in Patients with Metastatic Breast Cancer by Pretreatment with Low-Dose Intravenous Cyclophosphamide Journal of Immunotherapy ·Grant D. MacLean, D.W. Miles, R.D. Rubens, Mark A. Reddish, B. Michael Longenecker	1996	126
7	Safety and Immunogenicity of a Recombinant Multivalent Group A Streptococcal Vaccine in Healthy Adults JAMA ·Karen L. Kotloff, Mary C. Corretti, Kathleen Palmer, James D. Campbell, Mark A. Reddish, Mary C. Hu, Steven S. Wasserman, James B. Dale	2004	126
8	Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide International Journal of Cancer ·Mark A. Reddish, Grant D. MacLean, R. Rao Koganty, June Kan‐Mitchell, Vicky Jones, Malcolm S. Mitchell, B. Michael Longenecker	1998	108
9	Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: Effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene Cancer Immunology Immunotherapy ·Lei Ding, El–Nasir Lalani, Mark A. Reddish, R. Rao Koganty, Ting C. Wong, John Samuel, Mary Beth Yacyshyn, Alison Meikle, P Y Fung, Joyce Taylor-Papadimitriou, B. Michael Longenecker	1993	92
10	Evidence of a Cellular Immune Response Against Sialyl-Tn in Breast and Ovarian Cancer Patients After High-Dose Chemotherapy, Stem Cell Rescue, and Immunization with Theratope STn-KLH Cancer Vaccine Journal of Immunotherapy ·Brenda M. Sandmaier, Dimitry V. Oparin, Leona Holmberg, Mark A. Reddish, Grant D. MacLean, B. Michael Longenecker	1999	85
11	Liposomal Formulations of Synthetic MUC1 Peptides: Effects of Encapsulation versus Surface Display of Peptides on Immune Responses Bioconjugate Chemistry ·Holly H. Guan, W Budzyński, R. Rao Koganty, Mark J. Krantz, Mark A. Reddish, James A. Rogers, B. Michael Longenecker, John Samuel	1998	80
12	Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69 + lymphocytes correlate with effects of Theratope® sialyl-Tn-KLH cancer vaccine in active specific immunotherapy Cancer Immunology Immunotherapy ·Mark A. Reddish, Grant D. MacLean, Sibrand Poppema, Amy L. Berg, B. Michael Longenecker	1996	71
13	Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine International Journal of Cancer ·John Samuel, W Budzyński, Mark A. Reddish, Lei Ding, Gabrielle L. Zimmermann, Mark J. Krantz, R. Rao Koganty, B. Michael Longenecker	1998	69
14	Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells Cancer Immunology Immunotherapy ·Govindaswami Ragupathi, Lisa Howard, Sarah Cappello, R. Rao Koganty, Dongxu Qiu, B. Michael Longenecker, Mark A. Reddish, Kenneth O. Lloyd, Philip O. Livingston	1999	68
15	Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes Glycoconjugate Journal ·Mark A. Reddish, Linda Jackson, R. Rao Koganty, Dongxu Qiu, Wu Hong, B. Michael Longenecker	1997	66
16	Different modes of sialyl-Tn expression during malignant transformation of human colonic mucosa Glycoconjugate Journal ·Shunichiro Ogata, R. Rao Koganty, Mark A. Reddish, B. Michael Longenecker, Anli Chen, Carmen Ferrer‐Pérez, Steven H. Itzkowitz	1998	58
17	In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors The Journal of Immunology ·Babita Agrawal, Mark A. Reddish, B. Michael Longenecker	1996	56
18	Intranasal Immunization with Multivalent Group A Streptococcal Vaccines Protects Mice against Intranasal Challenge Infections Infection and Immunity ·Mary A. Hall, Steven D. Stroop, Mary C. Hu, Michael A. Walls, Mark A. Reddish, David S. Burt, George H. Lowell, James B. Dale	2004	53
19	Histamine-induced suppressor factor (HSF): inhibition of helper T cell generation and function. The Journal of Immunology ·Marvin R. Garovoy, Mark A. Reddish, Ross E. Rocklin	1983	49
20	Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. International Immunology ·Babita Agrawal, Mark J. Krantz, Mark A. Reddish, B. Michael Longenecker	1998	47

About Mark A. Reddish

Mark A. Reddish is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging, Immunology, Oncology and Public Health, Environmental and Occupational Health, having authored 32 papers that have together received 2.4k indexed citations. Recurring topics across this work include Glycosylation and Glycoproteins Research (19 papers), Monoclonal and Polyclonal Antibodies Research (18 papers), Immunotherapy and Immune Responses (15 papers), Streptococcal Infections and Treatments (5 papers), Immune Cell Function and Interaction (4 papers), Antimicrobial Resistance in Staphylococcus (4 papers), Cancer Research and Treatments (2 papers) and Infective Endocarditis Diagnosis and Management (2 papers). The work is most often cited by research in Immunology (1.1k citations), Infectious Diseases (521 citations), Radiology, Nuclear Medicine and Imaging (592 citations), Public Health, Environmental and Occupational Health (578 citations) and Molecular Biology (1.1k citations). Mark A. Reddish has collaborated with scholars based in Canada, United States and India. Frequent co-authors include B. Michael Longenecker, Grant D. MacLean, R. Rao Koganty, Mark J. Krantz, Babita Agrawal, James B. Dale, Steven D. Stroop, Alex Martin, W. Kyle Simmons and Patrick S.F. Bellgowan. Their work appears in journals such as Journal of Immunotherapy, Cancer Immunology Immunotherapy, International Journal of Cancer, Infection and Immunity and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact